This page describes pharmacological agents that may have legal restrictions, side effects, and drug interactions in your jurisdiction. Information is for educational research only — consult a clinician before considering any compound.
Surface here is educational only; do not use without medical supervision. Our editorial verdict is SKIP-FOR-NOW — current cost / risk / redundancy puts it below the line.
S-Acetyl-Glutathione
Acetylated, GI-stable form of glutathione (GSH) that improves oral bioavailability over plain GSH by ~13× in plasma AUC (Fanelli 2018) but…
Aliases (6)
Overview
What is S-Acetyl-Glutathione?
S-Acetyl-Glutathione (SAG) is an orally stable, acetylated form of the tripeptide glutathione (GSH) — the body's primary intracellular antioxidant. The acetyl group at the cysteine sulfur improves gut absorption and bioavailability over plain reduced glutathione, supporting cellular antioxidant capacity and detoxification.
Key Benefits
Raises intracellular glutathione, supports liver detoxification (Phase II conjugation), reduces oxidative stress markers, and may aid neuroprotection, immune balance, and skin appearance. Useful in aging, chronic inflammation, and heavy metal/xenobiotic burden.
Mechanism of Action
After oral absorption, SAG is deacetylated intracellularly to reduced glutathione (GSH). GSH neutralizes reactive oxygen species directly, recycles vitamins C and E, and acts as the rate-limiting cofactor for glutathione-S-transferases and glutathione peroxidases in detoxification and redox homeostasis.
▸Brand options6 known
StatusUnscheduled (OTC dietary supplement; GRAS pathway 2025)
Peptide Interactions
Complementary in theory — NAC supplies upstream cysteine substrate; SAG supplies downstream intact GSH delivered to cells. However, this stack is largely red…
Different antioxidant niche (lipid-soluble, mitochondrial membrane). Combines with SAG (water-soluble cytoplasmic) for layered ROS coverage. Both daily-safe …
Mitochondrial-energy + antioxidant pairing. ALCAR provides acetyl groups + carnitine for fatty-acid β-oxidation; SAG protects mitochondrial GSH pool from per…
Recycles oxidized GSH (GSSG) back to reduced GSH. Common functional-medicine stack pairing.
GSH and ascorbate cycle each other in the antioxidant network. V4 already includes 500 mg vitamin C.
Theoretical antagonism by reducing tumor oxidative stress. Not relevant for users in this archetype; flagged for completeness.
Redundant and expensive; pick one delivery form per goal.
Quality Indicators
Tested third-party COA
Reputable brands publish a Certificate of Analysis for identity, potency, and contaminant testing.
GMP-certified manufacturing
Look for cGMP / NSF / USP certifications on the label.
Proprietary blends
Avoid products that hide individual ingredient amounts inside a "proprietary blend."
No origin or sourcing info
Unbranded or no-COA capsules from anonymous sellers carry quality and adulteration risk.
What to Expect
- Week 1Baseline tolerability. Most chronic-use supplements have no acute signal.
- Week 2-4Subtle baseline shift — sleep quality, mood, recovery markers.
- Week 4-8Reach steady state. Re-assess subjective + objective markers.
- Month 3+Long-term maintenance dose if benefit confirmed; otherwise stop.
Side Effects & Safety
- Common (>10% users): None reliably. Most users report nothing acute.
- Less common (1-10%): Mild GI discomfort (nausea, soft stools, bloating), most often at >500 mg/day or when taken with food. Resolves with dose reduction or splitting. Sulfur-smelling burps reported (less than with NAC, but possible).
- Rare-serious (<1%):
- Asthma exacerbation (theoretical): Sulfhydryl compounds can rarely trigger bronchospasm in sulfite-sensitive asthmatics — this is well-documented for NAC and is theoretically possible for SAG. No published case reports specific to SAG.
- Drug-supplement interactions: Theoretical reduction of efficacy of chemotherapeutic agents that depend on oxidative stress for tumor killing (cisplatin, doxorubicin) — not relevant for users in this archetype but worth flagging for cancer patients.
- Specific watch periods: None standard. The 13-week rat tox profile is clean (Marone 2025); chronic human data >12 weeks is absent but no signal.
Upper safe intake: Not formally established for SAG. Plain glutathione is safe to ~2000 mg/day oral / ~3000 mg/week IV (Cymbiotika compilation). SAG's GRAS pathway (2025 Food Chem Toxicol review) supports doses tested in toxicology up to several hundred mg/kg/day in rats with no adverse findings.
References
Fanelli et al. 2018 — Oral Administration of S-acetyl-glutathione: Impact on the Levels of Glutathione in Plasma and in Erythrocytes of Healthy Volunteers (Int J Clin Nutr Diet)
principal human bioavailability study; n=18 crossover; ~13× plasma AUC vs plain GSH
View StudyCai et al. 2022 — S-Acetyl-Glutathione Attenuates Carbon Tetrachloride-Induced Liver Injury (PMC9024626)
mouse hepatic-injury model showing SAG raises tissue GSH and attenuates oxidative damage
View StudyMarone et al. 2025 — Safety assessment of S-Acetyl Glutathione for use in foods and dietary supplements (Food Chem Toxicol)
13-week rat toxicology, GRAS pathway support; flag: industry-authored
View StudyGnosis 2025 — Safety of S-Acetyl Glutathione confirmed for food and dietary supplements
supplier release of the 2025 safety review; conflict-of-interest flag
View StudyTandfonline 2023 — Effect of SAG diet supplement on glutathione peroxidase in healthy dogs
multi-ingredient canine pilot, off-species, confounded
View StudySchmitt et al. 2015 — Effects of N-acetylcysteine, oral glutathione (GSH) and a novel sublingual form of GSH on oxidative stress markers (PMC4536296)
sublingual GSH outperformed NAC and oral GSH on oxidative-stress markers; relevant comparator literature
View StudyAllen & Bradley 2011 — Randomized controlled trial of oral glutathione supplementation (PubMed 24791752)
plain oral GSH bioavailability baseline (poor)
View StudySinha 2018 — Liposomal Glutathione bioavailability (PMC discussions)
comparator showing liposomal > plain GSH on plasma peak and PBMC intracellular GSH
View StudyKumar et al. 2022 — A Targeted Metabolomic Assessment of Oral Glutathione Bioavailability and Safety in Humans (Antioxidants)
recent oral GSH metabolomics study
View StudyMDPI 2025 — Enhancing the Oral Bioavailability of Glutathione Using Innovative Analogue Approaches
2025 review of GSH analogues including SAG; surveys current bioavailability landscape
View StudySekhar et al. 2022 — RCT of Glycine + N-Acetylcysteine (GlyNAC) on glutathione redox status and oxidative damage in older adults (Frontiers in Aging)
GlyNAC alternative GSH-precursor strategy with elderly RCT evidence
View StudyMischley et al. 2017 — Central nervous system uptake of intranasal glutathione in Parkinson's disease (npj Parkinson's Disease)
intranasal GSH delivery as alternative route for brain GSH; relevant comparator
View StudyBrain Health University — NAC or Glutathione: Which Is a Better Brain Detoxifier?
practical comparison framing
View StudyResearched Nutritionals — Tri-Fortify Liposomal Glutathione
liposomal GSH product; published clinical research on intracellular GSH (28% PBMC increase)
View StudyQuicksilver Scientific — Liposomal Glutathione
alternative liposomal GSH product
View StudyCalifornia Gold Nutrition SAG (iHerb)
the user's likely budget vendor path if reconsidered
View StudyIntegrative Psychiatry — S-Acetyl Glutathione overview
typical functional-medicine marketing framing (treat with skepticism)
View StudyRTHM — S-Acetyl Glutathione Synergy for Long COVID/ME-CFS
chronic illness use-case framing
View StudyHow was your experience with this compound?
Anonymous · one vote per session · results below at 5+ votes.
See something off?
Most of this wiki is AI-generated. Suggest a correction, dosing update, or new evidence — we review every submission.